The Partnership Behind Artemis and UBC
Where time, place, and minds align.
Rooted in a heritage of learning and scientific rigor, and through our partnership with the University of British Columbia, Artemis honours the long arc of discovery — knowing that timing matters as much as insight.
A Partnership Rooted in Discovery
At the core of Artemis Therapeutics is a proprietary AI-driven discovery platform designed to accelerate the identification of safe and effective drug candidates. By integrating advanced computational methods with rigorous biological validation, Artemis transforms complex molecular data into precise, actionable insight.
The platform is already proven: six drug candidates identified using Artemis technology have been licensed to pharmaceutical partners. This success is grounded in a strong record of scientific excellence, including two international drug discovery competition wins led by Dr. Cherkasov.
Structured as an asset-driven biopharma company, Artemis advances its own therapeutic programs to capture the full value of innovation while maintaining strategic focus and scientific integrity. Its leadership team and Scientific Advisory Board include globally recognized pioneers in AI-enabled drug discovery, oncology, and translational medicine — bridging visionary science with disciplined execution.
OUR FOUNDERS
Leadership at the Intersection of AI, Science, and Medicine
Dr. Artem Cherkasov
Co-Founder & CTO
Pioneer in AI-driven drug discovery and creator of DeepDocking™
– Expert in computational chemistry and molecular modeling
– 20+ years advancing algorithms for drug discovery
– Author of 150+ publications and scientific contributions
Dr. Mads Daugaard
Co-Founder & CEO
Leader in translational medicine and therapeutic innovation
– Three decades in drug development and biotech leadership
– Former executive and board leadership roles
– Advocate for scientific integrity and patient impact
Let's Advance Discovery Together
If you are interested in partnering, investing, or exploring scientific collaboration, we welcome the conversation.